Immunomodulation and enhancement of antitumor activity by co-administration of 1,3-bis(2-chloroethyl)-1-nitrosourea and thymidine

Biochemical Pharmacology

Volumn 53, Issue 5, 1997, Pages 705-713

  Poo, Wen Jen H ^a   Guo, Xin ^a   Haslund, Benjamin ^a   Mozdziesz, Diane E ^a  

^a YALE CANCER CENTER   (United States)

Author keywords

1,3 bis(2 chloroethyl) 1 nitrosourea (BCNU); antitumor immune response; immunomodulation; melanoma; thymidine

Indexed keywords

CARMUSTINE; THYMIDINE;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; IMMUNOMODULATION; IN VITRO STUDY; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CARMUSTINE; FEMALE; HYPERSENSITIVITY, DELAYED; KILLER CELLS; LYMPHOCYTE ACTIVATION; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; THYMIDINE; TUMOR CELLS, CULTURED;

EID: 0030890979     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(96)00905-7     Document Type: Article

References (31)

1. Carter SK and Wasserman TH, The nitrosoureas - Thoughts for the future. Cancer Treat Rep 60: 807-811, 1976.
2. Wasserman TH, The nitrosoureas: An outline of clinical schedules and toxic effects. Cancer Treat Rep 60: 709-711, 1976.
3. DeVita VT, Carbon PP, Owens AH Jr, Gold GL, Krant MJ and Edmonson J, Clinical trials with 1,3-bis(2-chloroethyl)-1-nitrosourea, NSC-409962. Cancer Res 25: 1876-1881, 1965.
4. Weiss RB, Poster DS and Penta JS, The nitrosoureas and pulmonary toxicity. Cancer Treat Rev 8: 111-124, 1981.
5. Benz C, Choti M, Newcomer L and Cadman E, Thymidine enhancement of methotrexate and 5-fluorouracil toxicity in cultured human colon carcinoma. Cancer Chemother Pharmacol 12: 104-110, 1984.
6. Berger NA, Cantino DM and Vietti T, Synergistic antileukemia effect of 6-aminonicotinamide and 1,3-bis(2-chloroethyl)-1-nitrosourea on L1210 cells in vitro and in vivo. Cancer Res 42: 4382-4386, 1982.
7. Lin T-S and Prusoff WH, Enhancement of the anticancer activity of bis(2-chloroethyl)nitrosourea in mice by coadministration of 2′-deoxyuridine, 2′-deoxycytidine, or thymidine. Cancer Res 47: 394-397, 1987.
8. Fischer PH, Lin T-S, Chen MS and Prusoff WH, Specific protection against the cytotoxicity of a new class of nitrosoureas by pyrimidine deoxyribonucleosides. Biochem Pharmacol 28: 2973-2978, 1979.
9. Houghton AN, Vijayasaradhi S, Bouchard B, Naftzger C, Hara I and Chapman PB, Recognition of autoantigens by patients with melanoma. Ann NY Acad Sci 690: 59-68, 1993.
10. Schabel FM, Nitrosoureas: A review of experimental antitumor activity. Cancer Treat Rep 60: 665-702, 1976.
11. Feola J and Maruyama Y, Host resistance to tumor after cure of advanced LSA lymphoma by treatment with BCNU and chlorozotocin. Cancer Treat Rep 63: 1409-1412, 1979.
12. Sensi M, Bergomi M, Formelli F and Parmiani G, Eradication of a disseminated mouse lymphoma by 1,3-bis(2-chloroethyl)-1-nitrosourea is immunologically mediated and accompanied by de novo generation of antitumor cytotoxicity. Int J Cancer 46: 1088-1094, 1990.
13. Ramirez G, Wilson W, Grage T and Hill G, Phase II evaluation of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU: NSC-409962) in patients with solid tumors. Cancer Chemother Rep 56: 787-790, 1972.
14. Phillips GL, Fay JW, Herzig RH, Weiner RS, Wolff SN, Lazarus HM, Karanes C, Ross WE and Kramer BS, Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), NSC-409962 and cryopreserved autologous transplantation for refractory cancer: A phase I-II study. Cancer 52: 1792-1802, 1983.
15. Tchekmedyian NS, Tait N, Van Echo D and Aisner J, High-dose chemotherapy without autologous bone marrow transplantation in melanoma. J Clin Oncoi 4: 1811-1818, 1986.
16. Xeros N, Deoxyriboside control and synchronization of mitosis. Nature 194: 682-683, 1962.
17. Thomas DB and Lingwood CA, A model of cell cycle control: Effects of thymidine on synchronous cell culture. Cell 5: 37-42, 1975.
18. Martin DS, Stolfi RL, Sawyer RC, Rabindranath N, Spiegelman S, Young CW and Woodcock T, An overview of thymidine. Cancer 45: 1117-1128, 1980.
19. Kufe DW, Wick MM, Moschella S and Major P, Effect of high-dose thymidine infusions in patients with mycosis fungoides. Cancer 48: 1513-1516, 1981.
20. Lin T-S, Fischer PH, Marsh JC and Prusoff WH, Antitumor activity of the 3′-chloroethylnitrosourea analog of thymidine and the prevention by co-administered thymidine of lethality but not of anticancer activity. Cancer Res 42: 1624-1629, 1982.
21. August EM, Cooper DL and Prusoff WH, Inhibition of poly-(adenosine diphosphate-ribose) polymerase by thymidine and thymidine analogues in L1210 cells and its relationship to the potentiation of the antitumor activity of 1,3-bis(2-chloroethyl)-1-nitrosourea but not of 3′-[3-(2-chloroethyl)-3-nitrosoureido]-3′-deoxythymidine. Cancer Res 51: 1586-1590, 1991.
22. Nagarkatti M and Kaplan AM, The role of suppressor T-cells in BCNU-mediated rejection of a syngeneic tumor. J Immunol 135: 1510-1517, 1985.
23. Richards JM, Mehta N, Raming K and Skosey P, Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol 10: 1338-1343, 1992.
24. Brichard V, Van Pel A, Wolfel T, Wolfel C, De Plaen E, Lethe B, Coulie P and Boon T, The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 178: 489-495, 1993.
25. Naughton GK, Eisenger M and Bystryn JC, Antibodies to normal human melanocytes in vitiligo. J Exp Med 158: 246-251, 1983.
26. Nordlund JJ, Kirkwood JM, Forget BM, Milton DM, Albert DM and Lerner AB, Vitiligo in patients with melanoma. A good prognostic sign. J Am Acad Dermatol 9: 689-696, 1983.
27. Bystryn J-C, Rigel D, Friedman RJ and Kope A, Prognostic significance of hypopigmentation in malignant melanoma. Arch Dermatol 123: 1053-1055, 1987.
28. Laurie JA, Moertel CG, Fleming TR, Wieand HS, Leigh JE, Rubin J, McCormack GW, Gerstner JB, Krook JE, Malliard J, Twito DI, Morton RF, Tschetter LK and Barlow JF, Surgical adjuvant therapy of large bowel carcinoma: An evaluation of levamisole and the combination of levamisole and fluorouracil. J Clin Oncol 7: 1447-1456, 1989.
29. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, Veeder MH and Mailliard JA, Levamisole and fluorouracil for adjuvant therapy for resected colon carcinoma. N Engl J Med 322: 352-358, 1990.
30. Ikezawa Z, Regulation of the in vitro concanavalin A response of lymphocytes by cyclophosphamide-sensitive adherent cells. Jpn J Exp Med 50: 225-235, 1980.
31. Schultz MZ, Sandier AB, Durivage HJ and Cooper DL, A phase I pilot study of BCNU plus thymidine in patients with refractory cancer. Cancer Invest 14: 218-224, 1996.